Description

Learn about the discovery of immunodeficiencies leading to the use of pooled immunoglobulin as therapy, the struggle to use it intravenously and the eventual use in autoimmune disease.

• Intro :11
• In this episode :15
• Splitting Part 3 into two episodes :26
• Part A of the history of IV Ig and the antibody :53
• A recap on Cohn fractionation 2:40
• The history and uses of IV Ig 4:30
• What led to the recognition and research of primary immunodeficiencies 7:08
• How Charles Janeway Sr. paved the way for IV Ig from intramuscular Ig 9:01
• What are protein aggregates? 12:54
• Understanding the various mechanisms of Ig reactions 15:49
• Managing patients with low IgA and anti-IgA antibodies 18:36
• How to go from treating immunodeficiency to treating autoimmunity 21:40
• The modern understanding and mystery of IV Ig 25:30
• Quick summary 26:05
• Thanks for listening! 27:30

Disclosure: Brown reports no relevant financial disclosures.

We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum

References:

Barandun S, et al. Vox Sang. 1962;7:157-174.

Eibl MM. Immunol Allergy Clin North Am. 2008;28:737-764, viii.

Furusho K, et al. Lancet. 1983;2:1359.

Gallagher PE, Buckley RH. J Allergy Clin Immunol. 1982;69:120.

Guo Y, et al. Front Immunol. 2018;9:1299.

Imbach P, et al. Lancet. 1981;1:1228-31.

Intravenous Immunoglobulin: Prevention and Treatment of Disease. NIH Consens Statement Online. 1990;8:1-23.

Kustiawan I. PLoS ONE. 2018;13: e0195729. https://doi.org/10.1371/journal.pone.0195729.

MRC Working Party on Hypogammaglobulinaemia. Hypogammaglobulinaemia in the United Kingdom. London: Her Majesty's Stationery Office; 1971.

Oransky I. Lancet. 2003;362:409.

Sandler SG, et al. Transfus Med Rev. 1995;9:1-8.